A prospective study of epidemiology and pathogenesis of cytomegalovirus (CMV) infections in transplant recipients, previously reported for 30 patients (Clin. Res. XXII, 441A, 1974), has been extended to include 35 patients who have been studied clinically and virologically for 5 to 19 months after renal transplantation (RT) (except three patients who died within three months after RT). Active CMV infection was defined as presence of viremia, viruria, and/or a significant rise in the complement-fixing (CF) antibody titer. Immunosuppression was given since transplantation and included prednisone, azathioprine or cyclophosphamide, and, in some patients, antithymocyte globulin. Viremia was detected in 16 (46%) patients (mean onset 2.5 months after RT); viruria in 19 (54%) (mean onset 3.0 months after RT); antibody rise in 28 (80%) (mean onset 2.8 months after RT); thus 33 (94%) of 35 patients developed active infection by one or more criteria. One of the remaining two patients had CMV isolated from the lungs at death, one month after RT. Viremia was shortlived and may have been missed in some patients as sampling was done at monthly intervals. CMV did not infect medical staff personnel under observation during this study. Only 10% of patients had viruria or CF antibody rise during the hemodialysis pretransplantation phase of management, and less than 50% of patients received blood transfusions during the transplant operation. Thus, in most patients CMV infection appears to arise as a result of reactivation of a latent infection. Transfused blood may be a potential source of infection in those patients who received blood during or shortly before the surgery.
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A distinct clinical syndrome of arthralgias of large joints with or without fever developed in 21 (60%) of patients on the average 2.4 months after RT; in 17 of these its onset was within ± 1 month from the onset of active CMV infection. Eight patients developed, on the average 1.9 months after RT, pulmonary infiltrates which resolved spontaneously in five patients, whereas in three patients they were associated with bacterial (staphylococcal and pseudomonas) infection which led to patient's demise.
Mild hepatitis with SGPT levels above 200 Karmen units and serum bilirubin maximum levels between 2 to 6 mg/ 100 ml occurred in six patients at a mean interval of 3.4 months after RT. Twenty-four (69%) patients developed graft rejection (mean onset 1.2 months after RT) which was irreversible in 14 patients. The first episode of rejection occurred within + 1 month from the onset of active CMV infection in 21 of the 24 patients with rejection.
